CD274 and neoplasm: For PD-L1 CPS ≥ 1 tumor (22C3 assay), pembrolizumab and paclitaxel groups had mOS of 9.1 months (95% CI 6.2–10.7) and 8.3 months (95% CI 7.6–9.0), respectively (HR 0.82, 95% CI 0.66–1.03; one-sided p = 0.0421).